Elinor Bexe Lindskog (Elinor Bexe-Lindskog)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 16

Top Topics

Transforming Growth Factor

Gene Expression

Top Venues

Cancer immunology, immunotherapy : CII

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

This page only lists publications with an associated author ORCID identifier.

Publications

William Rodin, Louis Szeponik, Tsvetanka Rangelova, Firaol Tamiru Kebede, Tobias Österlund, Patrik Sundström, Stephen Hogg, Yvonne Wettergren, Antonio Cosma, Anders Ståhlberg, Elinor Bexe Lindskog, Marianne Quiding-Järbrink
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. Cancer immunology, immunotherapy : CII 73 (9) (2024)
William Rodin, Louis Szeponik, Tsvetanka Rangelova, Firaol Tamiru Kebede, Tobias Österlund, Patrik Sundström, Stephen Hogg, Yvonne Wettergren, Antonio Cosma, Anders Ståhlberg, Elinor Bexe Lindskog, Marianne Quiding-Järbrink
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. Cancer immunology, immunotherapy : CII 73 (9) (2024)
William Rodin, Louis Szeponik, Tsvetanka Rangelova, Firaol Tamiru Kebede, Tobias Österlund, Patrik Sundström, Stephen Hogg, Yvonne Wettergren, Antonio Cosma, Anders Ståhlberg, Elinor Bexe Lindskog, Marianne Quiding-Järbrink
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. Cancer immunology, immunotherapy : CII 73 (9) (2024)
William Rodin, Louis Szeponik, Tsvetanka Rangelova, Firaol Tamiru Kebede, Tobias Österlund, Patrik Sundström, Stephen Hogg, Yvonne Wettergren, Antonio Cosma, Anders Ståhlberg, Elinor Bexe Lindskog, Marianne Quiding-Järbrink
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Lana Ghanipour, Gabriella Jansson Palmer, Per J Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal, Jenny Brändstedt, Peter H Cashin
Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PloS one 19 (3) (2024)
William Rodin, Louis Szeponik, Tsvetanka Rangelova, Firaol Tamiru Kebede, Tobias Österlund, Patrik Sundström, Stephen Hogg, Yvonne Wettergren, Antonio Cosma, Anders Ståhlberg, Elinor Bexe Lindskog, Marianne Quiding-Järbrink
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Lana Ghanipour, Gabriella Jansson Palmer, Per J Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal, Jenny Brändstedt, Peter H Cashin
Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PloS one 19 (3) (2024)
William Rodin, Louis Szeponik, Tsvetanka Rangelova, Firaol Tamiru Kebede, Tobias Österlund, Patrik Sundström, Stephen Hogg, Yvonne Wettergren, Antonio Cosma, Anders Ståhlberg, Elinor Bexe Lindskog, Marianne Quiding-Järbrink
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Lana Ghanipour, Gabriella Jansson Palmer, Per J Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal, Jenny Brändstedt, Peter H Cashin
Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PloS one 19 (3) (2024)
Lana Ghanipour, Gabriella Jansson Palmer, Per J Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal, Jenny Brändstedt, Peter H Cashin
Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PloS one 19 (3) (2024)
Fanny Andric, Ala Al-Fairouzi, Yvonne Wettergren, Louis Szeponik, Elinor Bexe Lindskog, James C Cusack, Gerald Tumusiime, Marianne Quiding-Järbrink, David Ljungman
Immune Microenvironment in Sporadic Early-Onset versus Average-Onset Colorectal Cancer. Cancers 15 (5) (2023)
Fanny Andric, Ala Al-Fairouzi, Yvonne Wettergren, Louis Szeponik, Elinor Bexe Lindskog, James C Cusack, Gerald Tumusiime, Marianne Quiding-Järbrink, David Ljungman
Immune Microenvironment in Sporadic Early-Onset versus Average-Onset Colorectal Cancer. Cancers 15 (5) (2023)
Donia Kaidi, Louis Szeponik, Ulf Yrlid, Yvonne Wettergren, Elinor Bexe Lindskog
Impact of thymidine phosphorylase and CD163 expression on prognosis in stage II colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 24 (9) (2022)
Helena Taflin, Elisabeth Odin, Göran Carlsson, Bengt Gustavsson, Yvonne Wettergren, Elinor Bexe Lindskog
Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. Cancers 15 (1) (2022)
Helena Taflin, Elisabeth Odin, Göran Carlsson, Bengt Gustavsson, Yvonne Wettergren, Elinor Bexe Lindskog
Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. Cancers 15 (1) (2022)
Helena Taflin, Elisabeth Odin, Göran Carlsson, Bengt Gustavsson, Yvonne Wettergren, Elinor Bexe Lindskog
Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. Cancers 15 (1) (2022)